Olaparib an anticancer drug: A review
Rasiklal M. Dhariwal Institute of Pharmaceutical Education and Research, Chinchwad, Pune-411019, Maharashtra, India.
Review Article
World Journal of Advanced Research and Reviews, 2021, 11(02), 329-336
Article DOI: 10.30574/wjarr.2021.11.2.0406
Publication history:
Received on 21 July 2021; revised on 26 August 2021; accepted on 28 August 2021
Abstract:
Olaparib is an anti-cancer drug which comes under N-acyl piperazines class. The action of olaparib is PRPA inhibition. Drug taken by oral route which shows action in 1 to 3 hrs. after administration. It is FDA approved drug for various cancer treatment such as ovarian cancer, breast cancer, prostatic cancer and pancreatic cancer. Olaparib also useful different mutation conditions such as BRCA1/2 mutation. Olaparib prescribes after the chemotherapy treatment either singly or in combination. In serious and advanced mutation conditions combination therapy used. In this review paper, we put a narrative information about olaparib action, treatment approaches, pharmacokinetics, dosing regimen and resistance. Here we briefly give information about resistance mechanism of olaparib, treatment approaches in ovarian cancer, breast cancer and prostate cancer.
Keywords:
PRPA inhibition; BRCA mutation; Pharmacokinetic; Resistance; Dosing regimen
Full text article in PDF:
Copyright information:
Copyright © 2021 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0